VLX-1570

DB16030InvestigationalSmall molecule

VLX-1570 is under investigation in clinical trial NCT02372240 (A Study of VLX1570 and Dexamethasone in Myeloma Patients).

Mechanism: Pharmacologically active on Ubiquitin carboxyl-terminal hydrolase 14 and Ubiquitin carboxyl-terminal hydrolase isozyme L5
Curator reviewed
Formula / weight: C₂₃H₁₇F₂N₃O₆ · 469.401 g/mol (avg)
Also known as: (3E,5E)-3,5-Bis[(4-Fluoro-3-Nitrophenyl)Methylidene]-1-(Prop-2-Enoyl)Azepan-4-0Ne
Code names: VLX-1570

Resolves to

Compound

Structure

InChIKeySCKXBVLYWLLALY-CZCYGEDCSA-NSMILES[O-][N+](=O)C1=CC(\C=C2/CN(CC\C(=C/C3=CC(=C(F)C=C3)[N+]([O-])=O)C2=O)C(=O)C=C)=CC=C1F

Targets

What you can answer from here — as of July 08, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

7+ReferencesStructured and connected to the statements they support

Which drugs share a target with VLX-1570, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.